There are currently 47 active clinical trials seeking participants for Carcinoma, Non-Small-Cell Lung research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and New York.
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
NCT05456256
Recruiting
The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined patient population when LP-300 is co-administered with the standard of care chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone. This has been designed as a multi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Cancer Treatment Centers of America at Western Regional Medical Center, Goodyear, Arizona +11 locations
Conditions: Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
Register for Updates
Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
NCT05302817
Recruiting
Cancer radiation treatment plans that employ lung functional avoidance methods require 3D maps that differentiate regions of healthy lung function from regions of compromised tissue to deliver sufficient dose to the tumor while preserving as much functioning lung as possible. Hyperpolarized xenon-129 MRI can provide maps of ventilatory function and gas exchange to the bloodstream. Improving treatment plans based on this novel imaging modality could reduce risk or severity of radiation pneumoniti... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
01/19/2024
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
NCT05715229
Recruiting
This clinical trial plans to assess to what extent the on-treatment circulating tumor DNA (ctDNA) can predict the subset of patients with NSCLC who will respond to immunotherapy treatment only and which patients will need both immunotherapy and chemotherapy modalities for their treatment regimen.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia +2 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
NCT05461430
Recruiting
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/02/2024
Locations: xCures, Oakland, California
Conditions: Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Register for Updates
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Stage 4 Metastatic NSCLC
NCT06069570
Recruiting
This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with metastatic non-small cell lung cancer to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/11/2023
Locations: Beverly Hills Cancer Center & Optima Diagnostic Imaging, Beverly Hills, California +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Patient-centered, Optimal Integration of Survivorship and Palliative Care
NCT04900935
Recruiting
The goal of this study is to develop and test the feasibility of a supportive care model (POISE) for patients with metastatic Non-small Cell Lung Cancer (NSCLC). The main questions are is POISE feasible to deliver and acceptable to patients what is the effect of POISE on the distress patients feel related to their uncertain future, their confidence in their ability to manage cancer, and their understanding about what to expect Participants in the randomized controlled trial will receive either... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/20/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Stage IV Non-small Cell Lung Cancer, Targeted Therapy, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, ALK-positive Non-small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer, Palliative Care, Survivorship
Register for Updates
A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer
NCT05469178
Recruiting
The primary purpose of this study is to determine the safety and tolerability of the combination of bemcentinib with chemo-immunotherapy (CIT) to identify the recommended phase 2 dose (RP2D) when administered as first line (1L) treatment in participants with locally advanced (Stage IIIb/IIIC) or metastatic (Stage IV) non-squamous NSCLC with no actionable mutations and to determine the anti-tumor activity of the combination of bemcentinib with CIT when administered as 1L treatment in participants... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/06/2023
Locations: Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida +4 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
NCT02905591
Recruiting
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to a standard therapy for non-small cell lung cancer. The standard therapy is radiation therapy combined with carboplatin and paclitaxel (types of chemotherapy). All subjects will receive high-dose ascorbate in addition to the standard therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/15/2023
Locations: Holden Comprehensive Cancer Cener, Iowa City, Iowa
Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Register for Updates
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
NCT05577715
Recruiting
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/17/2023
Locations: Rocky Mountain Cancer Centers - Lone Tree, Lone Tree, Colorado +32 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
MYLUNG Consortium Part 3: Observational Study
NCT05885698
Recruiting
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2023
Locations: Southern Cancer Center, PC, Daphne, Alabama +16 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
NCT00100256
Recruiting
The purpose of this study is to determine the maximum dose that is safely tolerated of the experimental drug Rhenium Re 188 P2045. This will be done by first treating patients at relatively low doses of Rhenium Re 188 P2045, observing them closely to assure that there are no bad side effects, then increasing the dose when we are confident that it is safe to do so.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/31/2022
Locations: Not set, Iowa City, Iowa +1 locations
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Neoplasm Recurrence, Local
Register for Updates